RxDoctor Payments Data

Carolyn Moncure, NP

Nurse Practitioner · Richmond, VANPI 1215903497

Payments from drug & device makers

$2,045in general payments, 2019–2025

Across 119 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$652
  • Novo Nordisk$250
  • Abbott$231
  • Biohaven Pharmaceuticals, Inc.$188
  • Lilly USA, LLC$132
  • Dexcom, Inc.$73
  • plus $519 from 17 others

What the payments were for

  • Food & beverage$2,045100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,045 in reported general payments places this provider in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$18,852
Medicare patients
153
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$12,332
OzempicSemaglutide12$9,221
Spiriva HandihalerTiotropium Bromide11$5,669
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,503
SymbicortBudesonide/Formoterol Fumarate15$3,952
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,721
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$1,258
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,145
Rosuvastatin Calcium69$927
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide26$919
Fluoxetine Hcl19$781
Albuterol Sulfate HfaAlbuterol Sulfate28$755
Atorvastatin Calcium123$681
Ventolin HfaAlbuterol Sulfate12$670
Levothyroxine Sodium76$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$12,33215 claims
Novo NordiskOzempic$250$9,22112 claims
AstraZenecaSymbicort$17$3,95215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →